Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Role of SMPDL3B in obesity-associated non-alcoholic fatty liver disease

Award Number: R01DK131786
ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/01/2022
PERIOD OF PERFORMANCE END DATE: 04/30/2027

Group Awards By:

View Award Description

Role of SMPDL3B in obesity-associated non-alcoholic fatty liver disease - Obesity is an independent risk factor for development of non-alcoholic fatty liver disease (NAFLD). With the epidemic burden of obesity and metabolic diseases, NAFLD occurrence is steadily rising, along with the need for therapeutic options of this disease. Preliminary data from rodent and human studies provide strong evidence to support the hypothesis that monocyte/macrophage-derived TSP1 in obesity downregulates liver macrophage SMPDL3B and this downregulation feeds back to increase TSP1 binding to its receptor-CD36. This positive feedback loop together with SMPDL3B’s action on TLR pathways further amplifies liver macrophage pro-inflammatory signaling and leads to NAFLD progression. In this proposal, how SMPDL3B regulates CD36 function and then TSP1-CD36 dependent pro-inflammatory signaling in macrophages will be determined in Aim 1. The in vivo importance of macrophage SMPDL3B in NAFLD development and progression in both animal models and human liver organoids will be determined in Aim 2. Whether specific blockade of TSP1/CD36 interaction upregulates liver macrophage SMPDL3B and attenuates liver pro- inflammatory signaling and NAFLD development and progression will be determined in Aim 3. Completing these studies will provide novel information on the mechanisms by which suppressed macrophage SMPDL3B enhances liver macrophage pro-inflammatory signaling and its critical role in the progression of obesity- associated NAFLD to NASH. Further, testing a novel therapeutic application of a peptide nanoparticle conjugate to block TSP1/CD36 interaction in obesity-associated NASH in vivo will have translational significance.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $478,167 )
2026	2026	UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE	500 S LIMESTONE	LEXINGTON	KY	40526	FAYETTE	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	5	4/28/2026	NON-COMPETING CONTINUATION	$478,167
														Subtotal = $478,167

Issue Date FY: 2025 ( Subtotal = $478,167 )
2025	2025	UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE	500 S LIMESTONE	LEXINGTON	KY	40526	FAYETTE	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	4	4/28/2025	NON-COMPETING CONTINUATION	$478,167
														Subtotal = $478,167

Issue Date FY: 2024 ( Subtotal = $558,837 )
2024	2024	UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE	500 S LIMESTONE	LEXINGTON	KY	40526	FAYETTE	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	001	3	7/30/2024	SUPPLEMENT FOR EXPANSION	$99,797
2024	2024	UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE	500 S LIMESTONE	LEXINGTON	KY	40526	FAYETTE	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	3	5/27/2024	NON-COMPETING CONTINUATION	$459,040
														Subtotal = $558,837

Issue Date FY: 2023 ( Subtotal = $478,167 )
2023	2023	UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE	500 S LIMESTONE 109 KINKEAD HALL	LEXINGTON	KY	40526	FAYETTE	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	2	4/24/2023	NON-COMPETING CONTINUATION	$478,167
														Subtotal = $478,167

Issue Date FY: 2022 ( Subtotal = $491,417 )
2022	2022	UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE	500 S LIMESTONE 109 KINKEAD HALL	LEXINGTON	KY	40526	FAYETTE	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	6/24/2022	NEW	$491,417
														Subtotal = $491,417

Grand Total All Awards = $2,484,755

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Role of SMPDL3B in obesity-associated non-alcoholic fatty liver disease

Award Number: R01DK131786

ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/01/2022

PERIOD OF PERFORMANCE END DATE: 04/30/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer